The metabolic fate of izencitinib, a gut-selective pan-JAK inhibitor, in humans. Identification of unusual fecal metabolites and implications for MIST evaluation
- 9 September 2023
- journal article
- research article
- Published by Springer Nature in Medicinal Chemistry Research
- Vol. 32 (9) , 2071-2088
Abstract
No abstract availableKeywords
All Related Versions
This publication has 40 references indexed in Scilit:
- Current overview of extrinsic and intrinsic factors in etiology and progression of inflammatory bowel diseasesPharmacological Reports, 2014
- Update on Janus Kinase Antagonists in Inflammatory Bowel DiseaseGastroenterology Clinics of North America, 2014
- Contribution of Artifacts to N-Methylated Piperazine Cyanide Adduct Formation In Vitro from N-Alkyl Piperazine AnalogsDrug Metabolism and Disposition, 2013
- Reaction of Homopiperazine with Endogenous Formaldehyde: A Carbon Hydrogen Addition Metabolite/Product Identified in Rat Urine and BloodDrug Metabolism and Disposition, 2012
- Radiolabeled Absorption, Distribution, Metabolism, and Excretion Studies in Drug Development: Why, When, and How?Chemical Research in Toxicology, 2012
- Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritisJournal of Inflammation, 2010
- Human radiolabeled mass balance studies: objectives, utilities and limitationsBiopharmaceutics & Drug Disposition, 2009
- SulfasalazineAnnals of Internal Medicine, 1984
- Determination of mean valproic acid serum level by assay of a single pooled sampleClinical Pharmacology & Therapeutics, 1981
- Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reactionBiochemical Pharmacology, 1973